Advanced Therapies Journal

Advanced Therapies Journal

Overview of CAR-T Cell Therapy Application in Cancer

Reviewers

Authors
Mahtab Dolatabadi 1
Shabnam Radbakhsh 2
1 Kamali Hospital, Alborz University of Medical Science, Anesthesiology Department.
2 Department of Medical Biotechnology, School of Medicine Mashhad University of Medical Sciences, Mashhad, Iran.
10.22034/atj.2024.210461
Abstract
Genetically engineered T cells expressing chimeric antigen receptors (CARs) have shown notable therapeutic efficacy in persons with certain subtypes of B cell leukemia or lymphoma. Moreover, there is compelling evidence of their efficacy in individuals diagnosed with multiple myeloma. Nevertheless, several barriers impede the efficacy and widespread acceptance of CAR T cell treatment in these individuals, as well as in persons with other forms of cancer, particularly solid tumors. Significant challenges related to CAR T cells consist of severe toxicities, restricted capacity to travel to, infiltrate, and activate inside tumors, insufficient long-term persistence in the body, antigen evasion and variety, and issues in the manufacturing process. In order to expand the application of CAR T cells to a wider range of cancer types, it is crucial to enhance the designs of CARs beyond conventional structures. Investigators are using several engineering strategies to address the current challenges and improve the safety, efficacy, and user-friendliness of this therapy method. This paper presents an introduction to the CART cell, including its system of action, problems and limits, and its engineering.
Keywords
Solid Tumor
Chimeric antigen receptor
Immunotherapy
Adoptive-cell therapy
1.Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood cancer journal. 2021;11(4):69.
2.Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nature reviews Clinical oncology. 2023;20(6):359-71.
3.Schubert M-L, Schmitt M, Wang L, Ramos C, Jordan K, Müller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals of oncology. 2021;32(1):34-48.
4.Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nature reviews Clinical oncology. 2019;16(6):372-85.
5.Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer. American journal of hematology. 2019;94(S1):S3-S9.
6.Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N. CAR T cell therapy: A new era for cancer treatment. Oncology reports. 2019;42(6):2183-95.
7. Lamprecht M, Dansereau C. CAR T-Cell Therapy: Update on the state of the science. Clinical Journal of Oncology Nursing. 2019;23.
8.Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B. CAR-T cell therapy and infection: a review. Expert Review of Anti-Infective Therapy. 2021;19(6):749-58.
9. Abreu TR, Fonseca NA, Gonçalves N, Moreira JN. Current challenges and emerging opportunities of CAR-T cell therapies. Journal of Controlled Release. 2020;319:246-61.
10.Sermer D, Brentjens R. CAR T‐cell therapy: Full speed ahead. Hematological oncology. 2019;37:95-100.
11.Belge Bilgin G, Bilgin C, Burkett BJ, Orme JJ, Childs DS, Thorpe MP, et al. Theranostics and artificial intelligence: new frontiers in personalized medicine. Theranostics. 2024;14(6):2367-78.
12.Frey N. The what, when and how of CAR T cell therapy for ALL. Best Practice & Research Clinical Haematology. 2017;30(3):275-81.
13.Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer discovery. 2018;8(10):1219-26.
14.Almåsbak H, Aarvak T, Vemuri MC. CAR T cell therapy: a game changer in cancer treatment. Journal of immunology research. 2016;2016(1):5474602.
15.Newick K, O’Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annual review of medicine. 2017;68(1):139-52.
16.Kozani PS, Kozani PS, Rahbarizadeh F. Novel antigens of CAR T cell therapy: New roads; old destination. Translational Oncology. 2021;14(7):101079.
17.Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T cell therapy for solid tumors. International journal of biological sciences. 2019;15(12):2548.
18.Ahmad A. CAR-T cell therapy. MDPI; 2020. p. 4303.
19.Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nature Reviews Cancer. 2021;21(3):145-61.
20.Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Molecular Therapy-Oncolytics. 2016;3.
21.Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. Journal of hematology & oncology. 2017;10:1-11.
22.Lesch S, Benmebarek M-R, Cadilha BL, Stoiber S, Subklewe M, Endres S, et al., editors. Determinants of response and resistance to CAR T cell therapy. Seminars in Cancer Biology; 2020: Elsevier.
23.Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Molecular cancer. 2022;21(1):194.
24.June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-5.
25.Meng J, Wu X, Sun Z, Xun R, Liu M, Hu R, et al. Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a systematic review and meta-analysis. Frontiers in oncology. 2021;11:698607.
26.Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C-x, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. Journal of Experimental & Clinical Cancer Research. 2022;41(1):119.
27.Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Molecular Cancer. 2023;22(1):169.
28.Mazinani M, Rahbarizadeh F. CAR-T cell potency: from structural elements to vector backbone components. Biomarker research. 2022;10(1):70.
29.Wang X, Rivière I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Molecular Therapy-Oncolytics. 2016;3.
30. Zhang C, Liu J, Zhong JF, Zhang X. Engineering car-t cells. Biomarker research. 2017;5:1-6.
31. Skorka K, Ostapinska K, Malesa A, Giannopoulos K. The application of CAR-T cells in haematological malignancies. Archivum Immunologiae et Therapiae Experimentalis. 2020;68:1-19.
32.Marple AH, Bonifant CL, Shah NN, editors. Improving CAR T-cells: The next generation. Seminars in Hematology; 2020: Elsevier.
33.Kallam A, Vose JM. Recent advances in CAR-T cell therapy for non-Hodgkin lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2019;19(12):751-7.
34.Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, The Journal of the American Society of Hematology. 2015;125(26):4017-23.
35.Green DJ, Pont M, Sather BD, Cowan AJ, Turtle CJ, Till BG, et al. Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Blood. 2018;132(Supplement 1):1011-.
36.Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. Journal of Clinical Oncology. 2018;36(22):2267-80.
37.Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. The Journal of clinical investigation. 2016;126(8):3036-52.
38.Steentoft C, Migliorini D, King TR, Mandel U, June CH, Posey Jr AD. Glycan-directed CAR-T cells. Glycobiology. 2018;28(9):656-69.
39.Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang W-C, Yazaki P, et al. Effective targeting of TAG72+ peritoneal ovarian tumors via regional delivery of CAR-engineered T cells. Frontiers in immunology. 2018;9:2268.
40.Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clinical Cancer Research. 2019;25(8):2560-74.
41.Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, et al. Regional delivery of chimeric antigen receptor–engineered T cells effectively targets HER2+ breast cancer metastasis to the brain. Clinical Cancer Research. 2018;24(1):95-105.
42.Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Science translational medicine. 2014;6(261):261ra151-261ra151.
43.Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nature medicine. 2015;21(5):524-9.
44. Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. Journal of hematology & oncology. 2020;13:1-14.
45.Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. New England Journal of Medicine. 2018;378(5):449-59.
46.Gasciauskaite G, Lunkiewicz J, Spahn DR, Von Deschwanden C, Nöthiger CB, Tscholl DW. Environmental sustainability from anesthesia providers’ perspective: a qualitative study. BMC Anesthesiology. 2023;23(1):377.
47.Yáñez L, Sánchez-Escamilla M, Perales M-A. CAR T cell toxicity: current management and future directions. Hemasphere. 2019;3(2):e186.
48.Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood reviews. 2019;34:45-55.
49.Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine. 2017;377(26):2531-44.
50.Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine. 2018;378(5):439-48.
51.Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nature reviews Clinical oncology. 2018;15(1):47-62.
52.Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer discovery. 2018;8(8):958-71.
53.Watanabe K, Nishikawa H. Engineering strategies for broad application of TCR-T-and CAR-T-cell therapies. International Immunology. 2021;33(11):551-62.
54.Staveley-O’Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proceedings of the National Academy of Sciences. 1998;95(3):1178-83.
55.Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature reviews immunology. 2013;13(4):227-42.
56.Miyao K, Terakura S, Okuno S, Julamanee J, Watanabe K, Hamana H, et al. Introduction of genetically modified CD3ζ improves proliferation and persistence of antigen-specific CTLs. Cancer immunology research. 2018;6(6):733-44.
57.Govers C, Sebestyén Z, Roszik J, Van Brakel M, Berrevoets C, Szöőr Á, et al. TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity. The Journal of Immunology. 2014;193(10):5315-26.
58.Lin YC, Mahalingam J, Chiang JM, Su PJ, Chu YY, Lai HY, et al. Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. International journal of cancer. 2013;132(6):1341-50.
59.Guedan S, Madar A, Casado-Medrano V, Shaw C, Wing A, Liu F, et al. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. The Journal of clinical investigation. 2020;130(6):3087-97.
60.Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, et al. Multiple signaling roles of CD3ε and its application in CAR-T cell therapy. Cell. 2020;182(4):855-71. e23.
61.Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113-7.
62.Li W, Qiu S, Chen J, Jiang S, Chen W, Jiang J, et al. Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. Immunity. 2020;53(2):456-70. e6.
63. Boardman DA, Philippeos C, Fruhwirth GO, Ibrahim MA, Hannen RF, Cooper D, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. American Journal of Transplantation. 2017;17(4):931-43.
64. Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179-84.
65.Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 2016;44(6):1444-54.
66. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma. Journal of clinical oncology. 2015;33(15):1688-96.
67.Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558(7709):307-12.
68. Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature medicine. 2018;24(10):1499-503.
69.Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, et al. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. Leukemia. 2017;31(1):186-94.
 
Advanced Therapies Journal
Volume 6, Issue 21
Autumn 2024
Pages 28-40

  • Receive Date 13 October 2024
  • Revise Date 01 October 2024
  • Accept Date 10 November 2024